CureSearch to Award $1.2 Million to Young Investigators

This year, CureSearch for Children's Cancer will award twelve $100,000 grants to young investigators focused on innovative research offering the greatest potential to design treatments and improve the outcomes for children with difficult-to-treat cancer.

Recently, requests for applications for young investigators seeking funding in the areas of adolescents and young adults, liver tumors, soft tissue sarcomas, and brain tumors were issued while applicants who received approval of their Letters of Intent for the ALL, neuroblastoma, bone and kidney disease grants earlier in the year will submit full applications in September. Grants are designed as start-up funds for investigators who have concluded their post-doctoral training and are in the early stages of their research careers. Applicants will receive funding of up to $50,000 a year for two years.

Working with a panel of children's cancer research experts, CureSearch identified 12 areas of study that present the highest risk with the poorest outcomes for children with cancer. "We recognize that for many types of children's cancer, survival rates have not significantly increased in the past two decades," said Stuart Siegel, MD who is Chair of the CureSearch Board of Directors and Director of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles. "By strategically placing funds in the hand of researchers focused on these cancers, we hope to help move the needle so that more children have a chance for a cure."

CureSearch is seeking Young Investigators applying these advances to the field of children's cancer research in the following areas:

  • Relapsed acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Brain tumors (including studies of the blood brain barrier)
  • Bone tumors (Ewing sarcoma, osteosarcoma, etc.)
  • Liver tumors
  • Large cell lymphomas
  • Neuroblastoma
  • Rare tumors (retinoblastoma, germ cell, melanoma, thyroid, etc.)
  • Kidney tumors (high-risk Wilm's tumor, renal cell carcinoma, etc.)
  • Rhabdomyosarcoma and other soft tissue tumors (e.g., fibrosarcoma)
  • Adolescent and young adult cancers
  • Survivorship, wellness, and late effects

For those interested in applying, the final RFAs for this year will be for late effects of treatment, rare tumors, AML, and lymphoma and will be posted to Proposal Central in mid September.

Back to Main 

Christine Bork
Email Christine
(800) 458-6223

Childhood Cancer

Medical Information


Coping with Cancer

Get Involved

About Us